The increased subclonal neoantigen heterogeneity in HRD tumors may indicate less effective immunoediting and/or lower expansion of antigen specific CD8+ T cells responses to clonal neoantigens which are present on all the tumor cells. The gene discussed is CD8A; the disease is neoplasm.